CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.) クロビス・オンコロジ―



symbol CLVS
会社名 Clovis Oncology Inc (クロビス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ(ルカパリブ)及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん(BRCA)突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸(ADP)・リボースポリメラーゼ(PARP)阻害剤である。ルシチニブは、血管内皮増殖因子受容体(VEGFR)1-3、血小板由来増殖因子受容体(PDGFR)αとβ及び線維芽細胞増殖因子受容体(FGFR)1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体(EGFR)の経口突然変異選択的阻害剤である。   クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。   Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.
本社所在地 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-625-5000
設立年月日 39904
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 360人
EBITDA EBITDA(百万ドル) -268.68600
終値(lastsale) 30.34
時価総額(marketcap) 1597388590.94
時価総額 時価総額(百万ドル) 1531.05
売上高 売上高(百万ドル) 76.12600
企業価値(EV) 企業価値(EV)(百万ドル) 1423.143
当期純利益 当期純利益(百万ドル) -129.23100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income).



   That big R&D PARP win Clovis CEO Mahaffy touted a few weeks ago? The FDA isn''t buying it  2022/05/06 17:28:29 Endpoints News
Once again, you’ll have to go to the fine print in an SEC filing to find the bad news that has been steadily killing Clovis Oncology’s share price for years. Just weeks after Clovis did its level best to trumpet a big win for its stunted cash calf Rubraca in
   Clovis Oncology downgraded to neutral at Wainwright on Rubraca ovarian cancer uncertainty  2022/05/06 16:34:21 Seeking Alpha
H.C. Wainwright has downgraded Clovis Oncology (CLVS) to neutral from buy over concerns about a potential launch of Rubraca (rucaparib) as a first-line ovarian cancer treatment.
   Thinking about buying stock in Vinco Ventures, Digital Brands, Endo, Clovis Oncology, or Under Armour?  2022/05/06 14:55:00 Benzinga
NEW YORK , May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, DBGI, ENDP, CLVS, and UAA. … Full story available on
   Why Clovis Oncology Stock Was Plummeting This Week  2022/05/06 11:12:04 The Motley Fool
Investors bailed from the company after a quarterly results and operational update.
   Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference  2022/05/05 12:00:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
   Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts  2022/01/11 06:22:41 Seeking Alpha
   Is Now A Good Time To Invest In Clovis Oncology Inc. (NASDAQ: CLVS)?  2021/12/17 12:30:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) shares, rose in value on Thursday, 12/16/21, with the stock price down by -3.17% to the previous days close as strong demand from buyers drove the stock to $2.75. Actively observing the price movement in the last trading, the stock closed the session at $2.84, falling within a range of $2.72 Is Now A Good Time To Invest In Clovis Oncology Inc. (NASDAQ: CLVS)? Read More »
   Clovis Oncology Inc (CLVS): Price Now Near $2.66; Daily Chart Shows Downtrend on 20 Day Basis  2021/12/15 15:19:24 ETF Daily News
If you''re a trend trader, consider that the strongest clear trend on the daily chart exists on the 20 day timeframe. The post Clovis Oncology Inc (CLVS): Price Now Near $2.66; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .
   Zacks: Brokerages Expect Clovis Oncology (NASDAQ:CLVS) Will Announce Earnings of -$0.56 Per Share  2021/12/12 04:18:42 Transcript Daily
Wall Street brokerages expect Clovis Oncology (NASDAQ:CLVS) to announce earnings of ($0.56) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Clovis Oncologys earnings, with the lowest EPS estimate coming in at ($0.96) and the highest estimate coming in at ($0.32). Clovis Oncology reported earnings per share of []
   Clovis Oncology Inc. (CLVS) Outlook: Looking Back For Insights  2021/12/10 15:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) price on Thursday, December 09, fall -7.91% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.91. A look at the stocks price movement, the close in the last trading session was $3.16, moving within a range at $2.905 and $3.1592. The beta value Clovis Oncology Inc. (CLVS) Outlook: Looking Back For Insights Read More »
   Goldman Sachs Group Inc. Purchases 73,877 Shares of Clovis Oncology (NASDAQ:CLVS)  2021/11/27 09:40:41 Transcript Daily
Goldman Sachs Group Inc. lifted its position in shares of Clovis Oncology (NASDAQ:CLVS) by 25.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 361,026 shares of the biopharmaceutical companys stock after buying an additional 73,877 shares during the quarter. Goldman Sachs Group Inc.s []
   Ovarian Cancer Drug Market - Analysis & Forecasts to 2028 - Key Vendors are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology  2021/11/24 10:17:46 OpenPR
Global Ovarian cancer drug report deals with the new business challenges and investment research on the market which includes market attributes, industry structure, and competitive scenario, the problems, desire concepts, together with business strategies and market effectiveness. This is the
   If You’re A Risk-Taking Investor, Clovis Oncology Inc. (NASDAQ: CLVS) Is Worth Taking A Chance On.  2021/11/23 20:30:00 Marketing Sentinel
In today’s recent session, 1.09 million shares of the Clovis Oncology Inc. (NASDAQ:CLVS) have been traded, and its beta is 1.60. Most recently the company’s share price was $3.08, and it changed around -$0.04 or -1.31% from the last close, which brings the market valuation of the company to $418.70M. CLVS at last check was … If You’re A Risk-Taking Investor, Clovis Oncology Inc. (NASDAQ: CLVS) Is Worth Taking A Chance On. Read More »
   Should Clovis Oncology Inc. (NASDAQ: CLVS) Rally After -214.45% Drop From High?  2021/11/18 19:00:00 Marketing Sentinel
Clovis Oncology Inc. (NASDAQ:CLVS)’s traded shares stood at 1.56 million during the latest session, with the company’s beta value hitting 1.62. At the last check today, the stock’s price was $3.53, to imply a decrease of -2.75% or -$0.1 in intraday trading. The CLVS share’s 52-week high remains $11.10, putting it -214.45% down since that … Should Clovis Oncology Inc. (NASDAQ: CLVS) Rally After -214.45% Drop From High? Read More »
   Clovis Oncology Inc. (NASDAQ: CLVS): Surviving A Volatility  2021/11/17 16:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) price closed lower on Tuesday, November 16, dropping -1.03% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロビス・オンコロジ― CLVS Clovis Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)